The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo

Prostate

Volumn 72, Issue 6, 2012, Pages 677-689

  Wang, Xingya ^a   Chrysovergis, Kali ^a   Bienstock, Rachelle J ^a   Shim, Minsub ^a   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

H6D; NAG 1 GDF15; prostate cancer

Indexed keywords

ADIPONECTIN; CYCLIN D1; GROWTH DIFFERENTIATION FACTOR 15; LEPTIN; PROTEIN VARIANT; SOMATOMEDIN C;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTITUMOR GENE; ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE FUNCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NON STEROIDAL ANTI INFLAMMATORY DRUG ACTIVATED GENE 1; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; WEIGHT REDUCTION; WILD TYPE;

ADIPONECTIN; ALLELES; ANIMALS; CELL LINE, TUMOR; CYCLIN D1; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84858752954     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21471     Document Type: Article

References (50)

1. Cancer Facts and Figures. 2010. American Cancer Society.
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev 2007; 7 (4): 256-269. (Pubitemid 46486616)
3. Piek E, Heldin CH, Ten Dijke P,. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13 (15): 2105-2124.
4. Eling TE, Baek SJ, Shim M, Lee CH,. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006; 39 (6): 649-655. (Pubitemid 44892888)
5. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG, Brown DA, Stanley KK, Breit SN,. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 2000; 19 (10): 2212-2220. (Pubitemid 30259002)
6. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA, Thompson DD,. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998; 273 (22): 13760-13767. (Pubitemid 28268424)
7. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD,. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006; 98 (3): 342-350.
8. Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, Russell PK, Salamonsen LA, Wallace EM, Breit SN,. The transforming growth factors superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000; 85 (12): 4781-4788. (Pubitemid 32157666)
9. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, Mishina Y, Martin DW, Shoieb A, McEntee MF, Eling TE,. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006; 131 (5): 1553-1560. (Pubitemid 44708948)
10. Tan M, Wang Y, Guan K, Sun Y,. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA 2000; 97 (1): 109-114. (Pubitemid 30055792)
11. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN,. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003; 63 (16): 5034-5040. (Pubitemid 37022642)
12. Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ, Eling TE, Lucia MS,. Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006; 208 (3): 566-574. (Pubitemid 44141881)
13. Fairlie WD, Russell PK, Wu WM, Moore AG, Zhang HP, Brown PK, Bauskin AR, Breit SN,. Epitope mapping of the transforming growth factor-beta superfamily protein, macrophage inhibitory cytokine-1 (MIC-1): Identification of at least five distinct epitope specificities. Biochemistry 2001; 40 (1): 65-73. (Pubitemid 32052678)
14. Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, Hedelin M, Clark J, Stattin P, Meyers DA, Adami HO, Isaacs W, Gronberg H, Xu J,. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96 (16): 1248-1254. (Pubitemid 39232716)
15. Hayes VM, Severi G, Southey MC, Padilla EJ, English DR, Hopper JL, Giles GG, Sutherland RL,. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15 (6): 1223-1225.
16. Cheng I, Krumroy LM, Plummer SJ, Casey G, Witte JS,. MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16 (6): 1309-1311. (Pubitemid 46984978)
17. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN,. MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9 (7): 2642-2650. (Pubitemid 36842108)
18. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE,. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59 (4): 901-908. (Pubitemid 32274020)
19. Klein RD, Van Pelt CS, Sabichi AL, Dela Cerda J, Fischer SM, Furstenberger G, Muller-Decker K,. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 2005; 65 (5): 1808-1813. (Pubitemid 40478608)
20. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A,. Comparative protein structure modeling using Modeller. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al.]. 2006; Chapter 5: Unit 56.
21. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A,. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000; 29: 291-325. (Pubitemid 30599596)
22. Mimeault M, Batra SK,. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 224 (3): 626-635.
23. Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, Pinto LA,. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine 53 (3): 282-285.
24. van Kruijsdijk RC, van der Wall E, Visseren FL,. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18 (10): 2569-2578.
25. Papatsoris AG, Karamouzis MV, Papavassiliou AG,. Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005; 11 (2): 52-55. (Pubitemid 40193482)
26. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H,. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999; 59 (1): 227-233. (Pubitemid 29062982)
27. Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M,. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: A clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14 (5): 1270-1273. (Pubitemid 40656479)
28. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P,. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149 (7): 461-471, W483-468.
29. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C,. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6 (5): 1891-1895. (Pubitemid 30305086)
30. Hu H, Zhang J, Lee HJ, Kim SH, Lu J,. Penta-O-galloyl-beta- D -glucose induces S- and G(1)-cell cycle arrests in prostate cancer cells targeting DNA replication and cyclin D1. Carcinogenesis 2009; 30 (5): 818-823.
31. Dumont N, Arteaga CL,. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003; 3 (6): 531-536. (Pubitemid 36808648)
32. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, Yaghoutyfam N, Marquis CP, Stattin P, Pedersen NL, Adami HO, Gronberg H, Breit SN, Brown DA,. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): A new marker of all-cause mortality. Aging Cell 2010; 9 (6): 1057-1064.
33. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, Breit SN,. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006; 66 (10): 4983-4986. (Pubitemid 43852864)
34. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP,. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27 (49): 6365-6375.
35. Fantuzzi G,. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115 (5): 911-919, quiz 920.
36. Kim JH, Kim KY, Jeon JH, Lee SH, Hwang JE, Lee JH, Kim KK, Lim JS, Kim KI, Moon EY, Lee HG, Ryu JH, Yang Y,. Adipocyte culture medium stimulates production of macrophage inhibitory cytokine 1 in MDA-MB-231 cells. Cancer Lett 2008; 261 (2): 253-262.
37. Garofalo C, Surmacz E,. Leptin and cancer. J Cell Physiol 2006; 207 (1): 12-22.
38. Huang CY, Yu HS, Lai TY, Yeh YL, Su CC, Hsu HH, Tsai FJ, Tsai CH, Wu HC, Tang CH,. Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol. 2011; 226 (5): 1274-1282.
39. Singh SK, Grifson JJ, Mavuduru RS, Agarwal MM, Mandal AK, Jha V,. Serum leptin: A marker of prostate cancer irrespective of obesity. Cancer Biomark 7 (1): 11-15.
40. Barb D, Pazaitou-Panayiotou K, Mantzoros CS,. Adiponectin: A link between obesity and cancer. Expert Opin Investig Drugs 2006; 15 (8): 917-931.
41. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE,. Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. J Biol Chem 2002; 277 (29): 26662-26672. (Pubitemid 34967165)
42. Wahdan-Alaswad RS, Song K, Krebs TL, Shola DT, Gomez JA, Matsuyama S, Danielpour D,. Insulin-like growth factor i suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res 2010; 70 (22): 9106-9117.
43. Roberts CT Jr., IGF-1 and prostate cancer. Novartis Found Symp 2004; 262: 193-199, discussion 199-204, 265-198.
44. Lima GA, Correa LL, Gabrich R, Miranda LC, Gadelha MR,. IGF-I, insulin and prostate cancer. Arq Bras Endocrinol Metab 2009; 53 (8): 969-975.
45. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM,. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999; 59 (9): 2203-2209. (Pubitemid 29217686)
46. Kotzsch A, Nickel J, Seher A, Sebald W, Muller TD,. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J 2009; 28 (7): 937-947.
47. Nickel J, Kotzsch A, Sebald W, Mueller TD,. A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 2005; 349 (5): 933-947. (Pubitemid 40779617)
48. Schreuder H, Liesum A, Pohl J, Kruse M, Koyama M,. Crystal structure of recombinant human growth and differentiation factor 5: Evidence for interaction of the type I and type II receptor-binding sites. Biochem Biophys Res Commun 2005; 329 (3): 1076-1086. (Pubitemid 40341385)
49. Allendorph GP, Isaacs MJ, Kawakami Y, Izpisua Belmonte JC, Choe S,. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 2007; 46 (43): 12238-12247. (Pubitemid 350022378)
50. Kirsch T, Sebald W, Dreyer MK,. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 2000; 7 (6): 492-496. (Pubitemid 30414472)